IO Biotech, Inc. - IOBT STOCK NEWS

IO Biotech (Nasdaq: IOBT) announced positive results from its Phase 2 trial of IO102-IO103, a therapeutic cancer vaccine, in combination with Merck's KEYTRUDA® for advanced head and neck cancer. The study met its primary endpoint with a 44.4% overall response rate in PD-L1 high patients. Key findings include:

- 6.6-month median progression-free survival
- 66.7% disease control rate
- Safety profile consistent with previous data
- T-cell responses detected for both IO102 and IO103

The trial enrolled patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with PD-L1 CPS ≥ 20. These results support further investigation of the combination as a potential first-line treatment for metastatic and difficult-to-treat cancers.

IO Biotech (Nasdaq: IOBT) announced that the Independent Data Monitoring Committee (IDMC) recommended the continuation of its pivotal Phase 3 trial for IO102-IO103, a novel therapeutic cancer vaccine, in combination with KEYTRUDA® (pembrolizumab) for advanced melanoma. Key points:

1. No new safety signals observed
2. Primary endpoint of progression-free survival (PFS) projected for first half of 2025
3. Trial powered at 89% to detect a 35% reduction in event risk
4. 407 patients randomized
5. Interim analysis did not meet criteria for superiority in overall response rate (ORR)
6. Company remains optimistic based on Phase 1/2 results showing 25.5 months median PFS

IO Biotech also reported promising preliminary data from a Phase 2 basket trial in NSCLC and SCCHN, with upcoming presentations at medical conferences.

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines, has announced its participation in two upcoming investor conferences. The company's senior management will provide corporate updates and engage in one-on-one meetings at these events:

1. Morgan Stanley 22nd Annual Global Healthcare Conference in New York on September 4, 2024. CEO Mai-Britt Zocca, PhD, will participate in a fireside chat at 5:35 pm ET.

2. H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9, 2024. CFO Amy Sullivan will present at 10:30 am ET.

Webcasts of both presentations will be available on IO Biotech's website for 90 days following the events.

IO Biotech (Nasdaq: IOBT) reported Q2 2024 financial results and business highlights. Key points include:

1. Phase 3 interim analysis for IO102-IO103 in advanced melanoma expected in Q3 2024.
2. Completed enrollment in Phase 2 trials for NSCLC and SCCHN.
3. Data from SCCHN cohort accepted for ESMO 2024 presentation.
4. Ended Q2 with $100.7 million in cash, expected to support operations into Q4 2025.
5. Net loss of $20.7 million for Q2 2024, compared to $21.2 million in Q2 2023.
6. R&D expenses decreased to $15.8 million from $16.5 million year-over-year.
7. G&A expenses increased to $5.7 million from $5.3 million year-over-year.

IO Biotech (Nasdaq: IOBT) announced that an abstract on their lead therapeutic cancer vaccine candidate, IO102-IO103, has been accepted for poster presentation at the ESMO Congress 2024. The presentation will showcase data from a completed cohort of squamous cell carcinoma of the head and neck (SCCHN) patients in a Phase 2 basket trial combining IO102-IO103 with pembrolizumab.

The poster, titled 'A phase 2 trial of the IO102-IO103 vaccine plus pembrolizumab: completed cohort for first line (1L) treatment of advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)', will be presented on September 14, 2024, at the congress in Barcelona. This data represents a significant step in exploring IO102-IO103's potential across various solid tumors with high unmet medical needs.

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company, announced its participation at the Jefferies Global Healthcare Conference, occurring from June 4-6, 2024, in New York, NY.

The company's President and CEO, Mai-Britt Zocca, Ph.D., will present on June 5, 2024, from 7:30-7:55 AM EST, discussing IO Biotech’s development of novel cancer vaccines using their T-win® platform.

Additionally, both Dr. Zocca and CFO Amy Sullivan will engage in one-on-one meetings with investors during the conference. A webcast of the presentation will be available on the company's website for 90 days.

IO Biotech has reported its financial results for Q1 2024, highlighting a net loss of $19.5 million, up from $17.0 million in Q1 2023. Research and development expenses increased to $14.3 million, attributed to clinical trial activities for its cancer vaccine candidate, IO102-IO103. General and administrative expenses slightly decreased to $5.9 million. The company ended the quarter with $118 million in cash, down from $143.2 million in December 2023.

Key developments include the completion of patient enrollment in the pivotal Phase 3 trial of IO102-IO103 in combination with pembrolizumab for advanced melanoma. The interim analysis for the overall response rate (ORR) is expected in Q3 2024, and the primary endpoint of progression-free survival (PFS) in H1 2025. Additionally, Phase 2 trials IOB-022 and IOB-032 have progressed, with significant enrollment milestones achieved. The executive team has been strengthened with new hires to enhance business and commercial development.